Craft

Fresenius Kabi

Revenue

€7.9 B

FY, 2022

Fresenius Kabi Summary

Company Summary

Overview
Fresenius Kabi is a healthcare company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition. It offers biopharmaceuticals with a focus on autoimmune diseases and oncology, clinical nutrition products, and medical technologies, including vital disposables, infusion pumps, apheresis machines, cell therapy devices, etc. In addition, the company provides intravenously administered generic drugs across therapeutic categories such as oncology drugs, anesthetics and analgesics, anti-infectives, and critical care drugs.
Type
Subsidiary
Status
Active
Founded
1999
HQ
Bad Homburg, DE | view all locations
Website
https://www.fresenius-kabi.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Pierluigi Antonelli

    Pierluigi Antonelli, President and CEO

Operating MetricsView all

Certificates

13

Oct, 2023

Sales Representatives

70

Oct, 2023

Production Sites

60

Oct, 2023

LocationsView all

76 locations detected

  • Bad Homburg, HE HQ

    Germany

    Else-Kröner-Straße 1

  • Lake Zurich, IL

    United States

    Three Corporate Drive

  • Buenos Aires, CABA

    Argentina

    Av. Cabildo 2677 piso 10

  • Sydney, NSW

    Australia

    Level 2, 2 Woodland Way, Mount Kuring-Gai

  • Eugendorf, Salzburg

    Austria

    Pebering 19

  • Graz, Steiermark

    Austria

    Hafnerstraße 36

and 70 others

Fresenius Kabi Financials

Summary Financials

Revenue (Q1, 2023)
€2.0B
Net income (Q1, 2023)
€191.0M
EBIT (Q1, 2023)
€289.0M

Footer menu